| 10492ETCTN | Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer | Open |
| 1403GCC | An Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory Research | Open |
| 19108GCCC | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Open |
| 1950GCCC | First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND # Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer (NSCLCA) and advanced Mesothelioma | Open |
| 22110GCCC | Imaging Tumors with Hyperpolarized Carbon-13 Pyruvate ( HP-00101177) | Open |
| 2221GCCC | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors | Open |
| 2380GCC | A Single Arm phase I-II trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs based on Residual Circulating Tumor DNA (ctDNA) Levels (SAVAL) | Open |
| 2384GCC | Evaluation of Improved Onboard Patient Imaging With the HyperSight Platform on TrueBeam
4.0/4.1 | Open |
| EA3191 | EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features | Open |
| EAY191-A3 | A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers | Open |
| EAY191-N5 | A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors | Open |